Reflections on Plozasiran Trial Data and Future Potential

Author(s):

Kausik K. Ray, MD, MRCP: From the Department of Public Health,Gerald Watts, MD, PhD

Key Takeaways

Gene therapies, antisense oligonucleotides, and RNA interference technologies are promising approaches for FCS treatment, focusing on triglyceride reduction and symptom management.
Clinicians should engage in continuous education, attend conferences, and collaborate with specialists to integrate emerging therapies into practice.
A multidisciplinary approach and decision-support tools can enhance the management of FCS patients, improving outcomes.
Staying updated with ongoing research involves engaging with professional networks, subscribing to journals, and participating in clinical trials.

Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.

EP: 1.Familial Chylomicronemia Syndrome: Diagnosis, Genetic Factors, and Long-Term Health Implications

EP: 2.Quality of Life and Diagnostic Considerations for FCS

EP: 3.PALISADE Study: Plozasiran’s Efficacy and Potential in Reducing Triglycerides and Pancreatitis

EP: 4.Emerging Research of RNAi-Based Therapies for FCS

Now Viewing

EP: 5.Reflections on Plozasiran Trial Data and Future Potential

EP: 6.SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3

EP: 7.Novel Research Frontiers on the Management of FCS

Video content above is prompted by the following:

What other approaches have been tested or are in development for treating familial chylomicronemia syndrome (FCS)?

How can clinicians integrate emerging therapy advancements into their clinical practice for the management of FCS? What strategies should be adopted to stay updated with ongoing research and treatment options?